

**Generic Name:** pirtobrutinib

**Applicable Drugs:** Jaypirca®

**Preferred:** N/A

**Non-preferred:** N/A

**Date of Origin:** 11/13/2023

**Date Last Reviewed / Revised:** 11/13/2023

## PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I to VI are met)

- I. Diagnosis of relapsed or refractory mantle cell lymphoma
- II. Documented treatment failure after at least two lines of systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor
- III. Minimum age requirement: 18 years old
- IV. The medication is prescribed by an oncologist or hematologist.
- V. Request is for a medication with the appropriate FDA labeling, or its use is supported by current clinical practice guidelines.
- VI. Refer to the plan document for the list of preferred products. If the requested agent is not listed as a preferred product, must have documented treatment failure or contraindication to the preferred product(s).

## EXCLUSION CRITERIA

- N/A

## OTHER CRITERIA

- N/A

## QUANTITY / DAYS SUPPLY RESTRICTIONS

- 60 tablets per 30 days.

## APPROVAL LENGTH

- **Authorization:** 1 year
- **Re-Authorization:** Updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective (ie, there is no evidence of progressive disease while on Jaypirca therapy)

## APPENDIX

- N/A

## REFERENCES

1. Jaypirca. Prescribing information. Lilly USA LLC; 2023. Accessed October 2, 2023.  
<https://uspl.lilly.com/jaypirca/jaypirca.html#pi>
2. B-cell Lymphomas. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 5.2023. Updated July 7, 2023. Accessed September 10, 2023.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/b-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf)

**DISCLAIMER:** Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.